Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

BACKGROUND To our knowledge, UNION is the first phase 3 trial to assess a neoadjuvant strategy incorporating radiotherapy, immunotherapy, and chemotherapy compared with standard care in patients with locally advanced rectal cancer, which reported positive results for the primary endpoint (blinded independent review com...

Kai-Xiong Tao, Zhen-Yu Lin, Peng Zhang et al. · 0 citations
Clinical trial Open access Sep 2026

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

Bevacizumab plus chemotherapy is the standard first-line therapy for metastatic colorectal cancer (mCRC). To date, no phase 3 trial has compared first-line oral multitargeted TKI versus bevacizumab plus chemotherapy in RAS/BRAF wild-type mCRC. The open-label, noninferiority, randomized, phase 3 trial (ANCHOR; NCT048546...

Yue Liu, Yan-Qiao Zhang, Rongbo Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.